Skip to main content

Table 1 General clinical characteristics and tumor status

From: Long-term outcome of renal cell carcinoma in patients with HIV who undergo surgery

Feature

Total

HIV group

Control

N

67

33

34

Age at surgery

51 ± 11

51 ± 12

50 ± 11

BMI

24.8 ± 2.6

24.4 ± 2.2

25.1 ± 2.9

Gender

   

Female/Male

12/55

5/28

7/27

Creatinine

81.4 ± 16.5

77.1 ± 18.8

85.7 ± 12.9

eGFR

91.33 ± 17.29

94.69 ± 19.69

88.06 ± 14.15

CRP

10.92 ± 2.67

7.45 ± 3.78

14.94 ± 30.05

Albumin

42.5 ± 4.7

41.6 ± 4.8

43.4 ± 4.4

HGB (g/L)

126.6 ± 21.6

113.6 ± 12.6

139.3 ± 20.8

Tumor Size

4.42 ± 2.51

4.52 ± 2.95

4.33 ± 1.95

CD4 cell count(cell/)

523.3 ± 223.1

401.7 ± 210.1

641.3 ± 166.2

CD4/CD8 ratio

0.77 ± 0.37

0.68 ± 0.40

0.86 ± 0.33

Clinical Stage

   

 cT1

34

16

18

 cT2

25

13

12

 cT3

8

4

4

Pathological Stage

   

 pT1

46

24

21

 pT2

12

5

7

 pT3

10

4

6

Side

   

Left/Right

43/24

19/14

24/10

GPS

   

 0

40

20

20

 1

24

11

13

 2

3

2

1

Histology, n (%)

   

 Clear cell tumor

58

27

31

 Chromophobe cell tumor

6

5

1

 Other

3

1

2

Positive HBsAg, n (%)

4

3

1

Positive anti-HCV Ab, n (%)

3

1

2

CCI

7.58 ± 1.75

6.85 ± 1.18

8.69 ± 1.93

Baseline ART regimen

   

PI-based regimen

14

14

-

NNRTI-based regimen

18

18

-

INSTI-based regimen

1

1

-

Grade

   

 1

33

21

16

 2

24

8

13

 3

9

4

6

Surgical approach

   

 Partial resection

20

7

13

 Radical nephrectomy

47

26

21

Bleeding(mL)

135.7 ± 77.4

114.0 ± 51.8

169.2 ± 98.5

Operating Time(h)

1.3 ± 0.4

1.2 ± 0.4

1.4 ± 0.5

Length of stays

11.7 ± 3.8

11.8 ± 3.8

11.6 ± 3.9

KPS

90.3 ± 12.8

91.8 ± 13.1

88.8 ± 12.5

Leibovich Score 2003

1.22 ± 1.62(0–6)

1.27 ± 1.62

1.18 ± 1.66

  1. BMI Body mass index, eGFR estimated glomerular filtration rate, CRP C-reactive protein, HGB hemoglobin, CCI Charlson comorbidity index, GPS Glasgow Prognostic Score, ART active antiretroviral therapy, PI Protease inhibitor; NNRTI non-nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer inhibitor, KPS Karnofsky performance status